膜破坏减弱了前列腺类受体中激素的作用力
Uurtuya Hochban1, Imke Wallenstein1, Michaela Ulrich1
1Department of Pharmacy, Marburg University, Institute of Pharmacology and Clinical Pharmacy, Marburg, Germany.
The Biochemical journal
|September 29, 2025
概括
膜完整性显著影响G蛋白合受体 (GPCR) 功能,影响连接体结合亲和力. 这一发现对于准确的药物发现和对这些重要信号蛋白的结构研究至关重要.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- G蛋白结合受体 (GPCRs) 是关键的药物标,但它们的功能通常在破坏的膜环境中被研究.
- 膜完整性对GPCR功能和连接体结合的影响尚未被系统地研究.
研究的目的:
- 为了研究膜完整性对GPCR构成和连接体结合亲缘关系的影响.
- 开发和使用基于Förster共振能量转移 (FRET) 的传感器进行实时GPCR激活测量.
主要方法:
- 开发基于FRET的GPCR合规传感器.
- 在完整和破坏的细胞膜中测量GPCR激活.
- 在功能信号测试中使用野生型受体的验证.
主要成果:
- GPCRs对膜完整性有不同的依赖性;前列腺受体在膜破坏时显示连接体强度降低了30倍.
- 这表明膜完整性在确定连接体-受体亲和力方面发挥着关键作用.
- 证实了效应反映了真正的受体特征,而不是传感器工件.
结论:
- 膜完整性是影响GPCR连接体结合亲和力和功能的关键因素.
- 实验条件必须考虑膜完整性,以避免结构和药理学研究中的偏差.
- 优化的实验策略对于可靠的GPCR数据解释至关重要.
相关概念视频
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K
Drug-Receptor Interaction: Agonist
4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Drug-Receptor Interactions
7.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K
Opioid Receptors: Overview
4.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.1K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


